Edition:
India

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

23.91USD
2:29am IST
Change (% chg)

$-0.59 (-2.41%)
Prev Close
$24.50
Open
$24.59
Day's High
$25.07
Day's Low
$23.75
Volume
132,711
Avg. Vol
200,238
52-wk High
$26.73
52-wk Low
$7.37

Select another date:

BRIEF-Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA

* COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

BRIEF-Collegium receives FDA approval for sNDA for Xtampza® ER

* Collegium receives FDA approval for sNDA for Xtampza® ER Source text for Eikon: Further company coverage:

BRIEF-Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER

* Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER

Select another date: